entertainment -WSS

entertainment

author：hotspot 2025-09-27 09:58:38 - browse：77854

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： New brain studies show LSD's effects on the brain in full color

focus

WSS

Independent physicians launch a new lobbying group

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Why doctors need education on FDA device approval process

Parents surprise family after baby discharged from NICU after 170 days

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

leisure time

entertainment

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Elizabeth Holmes banned from government health programs

Medicare proposal to cover medical devices draws a mixed reaction

White House announces new plan to address the growing threat of xylazine in overdose crisis

BioMarin wins approval for gene therapy to treat hemophilia A

The surgeon had a dilemma only a Nazi medical text could resolve

Psychedelics group wrestles with new pharma identity

My yearlong odyssey to get my son’s ADHD medication covered

Anesthesiologist group: stop taking Ozempic before surgery

Biden declares emergency in flood

hotspot

EU regulator recommends expanding Mounjaro approval to obesity

Why doctors need education on FDA device approval process

The surgeon had a dilemma only a Nazi medical text could resolve

The surgeon had a dilemma only a Nazi medical text could resolve

The surgeon had a dilemma only a Nazi medical text could resolve

AI generated plenty of interest at JPM but not a lot of trust

leisure time

entertainment

focus

leisure time